Last reviewed · How we verify
NCT05258032: RADIS
Structural and Functional Characterization of Rare Ocular Diseases
trial in Retinitis Pigmentosa in 50 participants. Status unknown.
24 November 2024
Quick facts
| Lead sponsor | Barcelona Macula Foundation |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 24 November 2021 |
| Primary completion | 24 November 2024 |
| Estimated completion | 24 November 2025 |
| Sites | 1 location across Spain |
Conditions studied
- Retinitis Pigmentosa — all drugs for Retinitis Pigmentosa →
- Stargardt Disease 1 — all drugs for Stargardt Disease 1 →
- Best Disease — all drugs for Best Disease →
- Pattern Dystrophy of Macula — all drugs for Pattern Dystrophy of Macula →
Sponsor
Barcelona Macula Foundation
Who can join
18 and older, any sex, with Retinitis Pigmentosa or Stargardt Disease 1. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Rare ocular diseases (ROD) are a heterogeneous group of ocular diseases that affect very few people and, generally, for which no tretament is available. An important subgroup of these diseases are inherited retinal degenerations. In this study we focus on understanding the natural history of different ROD that affect the posterior segment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05258032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Retinitis Pigmentosa
Currently open trials in the same condition.
- NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years · Phase 1, PHASE2 · recruiting
- NCT07408232 — A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) · Phase 1, PHASE2 · recruiting
- NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06936787 — An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05258032 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Barcelona Macula Foundation
- Last refreshed: 15 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05258032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing